Dec 15, 2023, 06:25
Andrew Armstrong: Pleased to share our ARCHES analysis of efficacy, safety, and QOL of enza/ADT in men w/mHSPC by age
Andrew Armstrong, Professor of Medicine, Surgery, Pharmacology and Cancer Biology at the Duke Cancer Institute, shared on X/Twitter:
“Pleased to share our ARCHES analysis of efficacy, safety, and quality of life of enzalutamide (ENZA)/androgen-deprivation therapy (ADT) in men with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) by age (>75 vs <75) in the European Urology Oncology journal.”
For the article, click here.
Source: Andrew Armstrong/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 12, 2024, 21:03
Dec 12, 2024, 20:59
Dec 12, 2024, 20:55
Dec 12, 2024, 20:52
Dec 12, 2024, 20:49
Dec 12, 2024, 20:45
Dec 12, 2024, 20:39